Metabolic tumor volume—a biomarker derived from PET imaging—can more accurately predict progression-free survival for large B ...
Researchers found that loss of HDAC7 disrupted B-cell maturation in mouse models. Restoring HDAC7 suppressed tumor growth, ...
By enrolling the world's first participant, the Sarah Cannon Transplant & Cellular Therapy Program at St. David's South Austin Medical Center made this therapy available to patients before it was ...
Recent noteworthy reports on diffuse large B-cell lymphoma (DLBCL) include positive survival results with an antibody-drug conjugate in relapsed/refractory disease, FDA issues with a randomized trial, ...
How Can Biomarkers Help Individualize Treatment of Diffuse Large B-cell Lymphoma? Using Biomarkers to Diagnose Diffuse Large B-cell Lymphoma ...
Patients dosed in Phase 1 safety and tolerability study of MDX2003, a novel T-cell engager designed to optimize killing of lymphomasPreclinical ...
Researchers assessed whether using bispecific antibodies targeting CD20 and CD3 would reduce efficacy or increase toxicity in patients with relapsed or refractory non-Hodgkin B-cell lymphomas ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), presented today results from the Phase III SUNMO [NCT05171647] study showing Lunsumio ...
Incyte (Nasdaq:INCY) today announced that full results from the Phase 3 pivotal study evaluating tafasitamab (Monjuvi ® /Minjuvi ®) in first-line diffuse large b-cell lymphoma (DLBCL) will be featured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results